China: How to keep up and win in the world's fastest changing healthcare market
China's population will start to shrink in 2023 placing greater weight on the working population who have to support increasing numbers of 65+ year olds. The aging population combined with a surge in non-communicable diseases has led to a higher disease burden and more pressure on an already overstretched healthcare system. Seeking to modernise, China has undertaken a range of reforms.
ISPOR Annual Conference 2019
Last month, Directors Brett Gardiner and Rachel Howard attended the ISPOR annual conference in New Orleans.
With over 4,000 delegates in attendance and a three-day program packed with panel presentations, poster sessions, educational symposia and workshops, this is the leading global conference for health economics and outcomes research.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).
World Pharma Pricing and Market Access Congress 2019
Last month, Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam.
This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy.